Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
- PMID: 17565025
- DOI: 10.1378/chest.06-2674
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
Abstract
A consensus panel convened by the American College of Chest Physicians developed guidelines for the treatment of pulmonary arterial hypertension (PAH) that were published in 2004. Subsequently, several important clinical trials have been published, and new treatments have received regulatory approval. In addition, add-on and combination therapy are being explored, which promise to open new therapeutic avenues. This article, taking into consideration studies published prior to September 1, 2006, provides an update to the previously published guidelines. The original guidelines have been summarized, a discussion of new studies has been added, and the treatment algorithm has been revised to take into account recent developments in therapy. This update provides evidence-based treatment recommendations for physicians involved in the care of patients with PAH. Due to the complexity of the diagnostic evaluation required and the treatment options available, referral of patients with PAH to a specialized center continues to be strongly recommended.
Similar articles
-
Evidence-based pharmacologic management of pulmonary arterial hypertension.Clin Ther. 2007 Oct;29(10):2134-53. doi: 10.1016/j.clinthera.2007.10.009. Clin Ther. 2007. PMID: 18042471 Review.
-
Current treatment strategies for pulmonary arterial hypertension.J Intern Med. 2005 Sep;258(3):199-215. doi: 10.1111/j.1365-2796.2005.01542.x. J Intern Med. 2005. PMID: 16115293 Review.
-
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.Chest. 2004 Jul;126(1 Suppl):35S-62S. doi: 10.1378/chest.126.1_suppl.35S. Chest. 2004. PMID: 15249494
-
Role of combination therapy in the treatment of pulmonary arterial hypertension.Pharmacotherapy. 2010 Apr;30(4):390-404. doi: 10.1592/phco.30.4.390. Pharmacotherapy. 2010. PMID: 20334459 Review.
-
Combination pharmacotherapy in the treatment of pulmonary arterial hypertension: continuing education article.J Pharm Pract. 2013 Feb;26(1):18-28. doi: 10.1177/0897190012466046. J Pharm Pract. 2013. PMID: 23420762 Review.
Cited by
-
An in-depth evaluation of the efficacy and safety of various treatment modalities for chronic thromboembolic pulmonary hypertension: A systematic review and network meta-analysis.Am Heart J Plus. 2024 Sep 24;46:100466. doi: 10.1016/j.ahjo.2024.100466. eCollection 2024 Oct. Am Heart J Plus. 2024. PMID: 39399578 Free PMC article. Review.
-
The Long-Term Response to Treatment with Calcium Channel Blockers in Patients with Idiopathic Pulmonary Arterial Hypertension.J Tehran Heart Cent. 2023 Jan;18(1):62-67. doi: 10.18502/jthc.v18i1.12583. J Tehran Heart Cent. 2023. PMID: 37252215 Free PMC article.
-
Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS).Pulm Circ. 2022 Oct 1;12(4):e12150. doi: 10.1002/pul2.12150. eCollection 2022 Oct. Pulm Circ. 2022. PMID: 36381290 Free PMC article.
-
Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America.Pulm Circ. 2022 Jan 12;12(1):e12012. doi: 10.1002/pul2.12012. eCollection 2022 Jan. Pulm Circ. 2022. PMID: 35506085 Free PMC article.
-
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.Eur Respir J. 2022 Jun 2;59(6):2101552. doi: 10.1183/13993003.01552-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34675044 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
